Trial Design and Baseline Characteristics from REMODEL: A Mechanistic Study of Semaglutide vs. Placebo in People with Type 2 Diabetes and CKD

Authors: David Cherney, Petter Bjornstad, Milenta Mariam Chacko, Thomas P. Gunnarsson, Jeffrey B. Hodgin, Matthias Kretzler, Nicolas Belmar, Menno Pruijm, Philip Andreas Schytz, Katherine R. Tuttle

Published: 2024-10-28

DOI: 10.1681/asn.2024wcjmwep0

Keywords: No keywords found.

Abstract:
No abstract found.

Source: